ASX Penny Stocks Highlight: DUG Technology Featured Among Three Key Selections
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 15 2025
0mins
Should l Buy IMMP?
Source: Yahoo Finance
Market Overview: Australian shares are facing challenges due to global tech sector declines, prompting investors to consider penny stocks, which may offer surprising value and stability despite their smaller size.
DUG Technology Ltd: This technology company, with a market cap of A$281.66 million, has shown improvement in financial health, reducing losses significantly over the past five years, and has potential for future growth despite current profitability challenges.
Immutep Limited: A biotechnology firm focused on immunotherapies, Immutep has a market cap of A$552.65 million and is well-positioned financially, with a strong cash position supporting ongoing clinical trials, despite being pre-revenue.
Wagners Holding Company: With a market cap of A$719.01 million, Wagners has demonstrated robust financial health and significant earnings growth, supported by its inclusion in the S&P/ASX Emerging Companies Index, although it faces challenges with long-term liabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMP
Wall Street analysts forecast IMMP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.370
Low
12.00
Averages
12.00
High
12.00
Current: 0.370
Low
12.00
Averages
12.00
High
12.00
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immutep Faces Securities Claims Investigation
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) for possibly issuing materially misleading business information, indicating significant risks in the company's information disclosure practices.
- Stock Price Plunge: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, reflecting extreme market pessimism regarding the company's future prospects.
- Class Action Preparation: The Rosen Law Firm is preparing a class action against Immutep, allowing investors to seek compensation without any out-of-pocket fees, suggesting that the legal risks faced by the company could have profound implications for its financial health.
- Law Firm's Expertise: The Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its professional capability and influence in handling such cases.
See More
Immutep Under Investigation for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating claims on behalf of investors of Immutep Limited regarding potential securities fraud or unlawful business practices by the company and its executives, highlighting serious concerns over corporate governance.
- Trial Discontinuation: On March 13, 2026, Immutep announced the discontinuation of its TACTI-004 Phase III study based on the Independent Data Monitoring Committee's recommendation, indicating that the drug's efficacy in non-small cell lung cancer patients did not meet expectations, which may impact the company's future R&D direction.
- Stock Price Plunge: Following the trial discontinuation announcement, Immutep's American Depositary Receipt (ADR) price plummeted by 82.44%, dropping from $2.27 to $0.48, reflecting market pessimism regarding the company's outlook.
- Legal Implications: The investigation could lead to class action lawsuits against Immutep, exacerbating the trust crisis among investors regarding the management team, which may affect the company's ability to raise funds and its market reputation.
See More
Immutep Under Investigation for Possible Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating Immutep Limited for potential securities fraud involving its officers, which could lead to significant losses for investors and undermine trust in the company.
- Trial Termination: On March 13, 2026, Immutep announced the discontinuation of its TACTI-004 Phase III study based on the Independent Data Monitoring Committee's recommendation, indicating insufficient efficacy of the drug in non-small cell lung cancer patients, which may alter the company's future R&D strategy.
- Stock Price Plunge: Following the trial termination announcement, Immutep's American Depositary Receipt (ADR) price plummeted by 82.44%, dropping from $2.27 to $0.48, reflecting the market's pessimistic outlook on the company's future prospects.
- Legal Implications: The investigation could lead to class action lawsuits against Immutep, with Pomerantz LLP, a prominent securities litigation firm, potentially seeking compensation for affected investors, thereby increasing the legal risks faced by the company.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) due to allegations of misleading business information, highlighting serious concerns regarding the company's transparency and investor trust.
- Lawsuit Preparation: The firm is preparing a class action to seek compensation for investors who purchased Immutep securities without any upfront costs, which may encourage more affected investors to join the action and recover losses.
- Clinical Trial Discontinuation: On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 Phase III clinical trial for non-small cell lung cancer based on recommendations from the Independent Data Monitoring Committee, leading to an 82.6% drop in stock price, reflecting market pessimism about the company's future prospects.
- Market Reaction: Following the trial discontinuation announcement, Immutep's American Depositary Receipt (ADR) price fell by $2.28 to close at $0.48, indicating a significant loss of investor confidence in the company's governance and future development.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims on behalf of Immutep Ltd. (NASDAQ:IMMP) shareholders due to allegations of misleading business information, aiming to protect investor rights and seek compensation.
- Stock Price Plunge Impact: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, to close at $0.48 after the Independent Data Monitoring Committee recommended discontinuation of the TACTI-004 Phase III study, severely impacting investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action where investors can participate without any out-of-pocket fees, indicating the firm's commitment to recovering losses for affected investors and enhancing its reputation in securities litigation.
- Firm's Strength: The Rosen Law Firm recovered over $438 million for investors in 2019 and was ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its strong capabilities and successful track record in the securities litigation field.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) for allegedly issuing materially misleading business information, emphasizing the firm's commitment to protecting investor rights.
- Lawsuit Preparation: The firm is preparing a class action to recover losses for investors who purchased Immutep securities, allowing participation without any upfront fees, thereby lowering the barrier for affected investors to seek compensation.
- Stock Price Plunge: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, reflecting a pessimistic outlook from the market regarding the company's future.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling such cases.
See More
Immutep Faces Securities Claims Investigation
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) for possibly issuing materially misleading business information, indicating significant risks in the company's information disclosure practices.
- Stock Price Plunge: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, reflecting extreme market pessimism regarding the company's future prospects.
- Class Action Preparation: The Rosen Law Firm is preparing a class action against Immutep, allowing investors to seek compensation without any out-of-pocket fees, suggesting that the legal risks faced by the company could have profound implications for its financial health.
- Law Firm's Expertise: The Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its professional capability and influence in handling such cases.
See More
Immutep Under Investigation for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating claims on behalf of investors of Immutep Limited regarding potential securities fraud or unlawful business practices by the company and its executives, highlighting serious concerns over corporate governance.
- Trial Discontinuation: On March 13, 2026, Immutep announced the discontinuation of its TACTI-004 Phase III study based on the Independent Data Monitoring Committee's recommendation, indicating that the drug's efficacy in non-small cell lung cancer patients did not meet expectations, which may impact the company's future R&D direction.
- Stock Price Plunge: Following the trial discontinuation announcement, Immutep's American Depositary Receipt (ADR) price plummeted by 82.44%, dropping from $2.27 to $0.48, reflecting market pessimism regarding the company's outlook.
- Legal Implications: The investigation could lead to class action lawsuits against Immutep, exacerbating the trust crisis among investors regarding the management team, which may affect the company's ability to raise funds and its market reputation.
See More
Immutep Under Investigation for Possible Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating Immutep Limited for potential securities fraud involving its officers, which could lead to significant losses for investors and undermine trust in the company.
- Trial Termination: On March 13, 2026, Immutep announced the discontinuation of its TACTI-004 Phase III study based on the Independent Data Monitoring Committee's recommendation, indicating insufficient efficacy of the drug in non-small cell lung cancer patients, which may alter the company's future R&D strategy.
- Stock Price Plunge: Following the trial termination announcement, Immutep's American Depositary Receipt (ADR) price plummeted by 82.44%, dropping from $2.27 to $0.48, reflecting the market's pessimistic outlook on the company's future prospects.
- Legal Implications: The investigation could lead to class action lawsuits against Immutep, with Pomerantz LLP, a prominent securities litigation firm, potentially seeking compensation for affected investors, thereby increasing the legal risks faced by the company.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) due to allegations of misleading business information, highlighting serious concerns regarding the company's transparency and investor trust.
- Lawsuit Preparation: The firm is preparing a class action to seek compensation for investors who purchased Immutep securities without any upfront costs, which may encourage more affected investors to join the action and recover losses.
- Clinical Trial Discontinuation: On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 Phase III clinical trial for non-small cell lung cancer based on recommendations from the Independent Data Monitoring Committee, leading to an 82.6% drop in stock price, reflecting market pessimism about the company's future prospects.
- Market Reaction: Following the trial discontinuation announcement, Immutep's American Depositary Receipt (ADR) price fell by $2.28 to close at $0.48, indicating a significant loss of investor confidence in the company's governance and future development.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims on behalf of Immutep Ltd. (NASDAQ:IMMP) shareholders due to allegations of misleading business information, aiming to protect investor rights and seek compensation.
- Stock Price Plunge Impact: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, to close at $0.48 after the Independent Data Monitoring Committee recommended discontinuation of the TACTI-004 Phase III study, severely impacting investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action where investors can participate without any out-of-pocket fees, indicating the firm's commitment to recovering losses for affected investors and enhancing its reputation in securities litigation.
- Firm's Strength: The Rosen Law Firm recovered over $438 million for investors in 2019 and was ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its strong capabilities and successful track record in the securities litigation field.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) for allegedly issuing materially misleading business information, emphasizing the firm's commitment to protecting investor rights.
- Lawsuit Preparation: The firm is preparing a class action to recover losses for investors who purchased Immutep securities, allowing participation without any upfront fees, thereby lowering the barrier for affected investors to seek compensation.
- Stock Price Plunge: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, reflecting a pessimistic outlook from the market regarding the company's future.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling such cases.
See More
